Anticancer Drugs Practice Questions

Q: Which is the most cardiotoxic anticancer drug class?

Anthracyclines. **Explanation:** **1. Why Anthracyclines are the correct answer:** Anthracyclines (e.g., **Doxorubicin, Daunorubicin**) are notorious for causing dose-dependent, cumulative cardiotoxicity. The underlying mechanism involves the generation of **reactive oxygen species (ROS)** and the formation of iron-anthracycline complexes. These lead to lipid peroxidation of the myocardial cell membrane and damage to the sarcoplasmic reticulum. Unlike other tissues, the heart is particularly vulnerable because it has low levels of antioxidant enzymes like catalase and superoxide dismutase. This can manifest as acute arrhythmias or, more commonly, chronic **congestive heart failure (CHF)**. **2. Why other options are incorrect:** * **Alkylating agents (e.g., Cyclophosphamide):** While high doses can cause hemorrhagic cystitis (prevented by Mesna) or acute myocarditis, they are primarily known for bone marrow suppression and secondary malignancies, not chronic cardiotoxicity. * **Platinum compounds (e.g., Cisplatin):** These are primarily associated with **nephrotoxicity** and **ototoxicity**. They do not typically cause significant cardiotoxicity. * **Bisphosphonates:** These are not primary anticancer drugs but are used to treat bone metastases and hypercalcemia. Their main side effects include osteonecrosis of the jaw and esophageal irritation. **3. NEET-PG High-Yield Clinical Pearls:** * **Dexrazoxane:** An iron chelator used to prevent/reduce doxorubicin-induced cardiotoxicity. * **Monitoring:** Patients on Anthracyclines should have regular **ECHO/MUGA scans** to monitor the Left Ventricular Ejection Fraction (LVEF). * **Trastuzumab (Herceptin):** Another cardiotoxic drug (monoclonal antibody), but unlike Anthracyclines, its toxicity is usually **reversible** and not dose-dependent. * **Lifetime Dose:** The risk of CHF increases significantly once the cumulative dose of Doxorubicin exceeds **450–550 mg/m²**.

Q: A patient with Non-Hodgkin's Lymphoma (NHL) is being treated with the CHOP chemotherapy regimen. Which of the listed agents is most likely to be protective against the cardiotoxicity associated with doxorubicin?

Dexrazoxane. **Explanation:** **1. Why Dexrazoxane is the correct answer:** Doxorubicin (the ‘H’ or Hydroxydaunorubicin in the CHOP regimen) causes dose-dependent cardiotoxicity. The underlying mechanism involves the formation of **iron-anthracycline complexes** that generate reactive oxygen species (ROS), leading to lipid peroxidation and cardiomyocyte death [1]. **Dexrazoxane** is an iron-chelating agent that enters cardiac cells and interferes with iron-mediated free radical formation [1]. It also inhibits Topoisomerase IIβ, further protecting the heart. It is specifically FDA-approved to reduce the incidence and severity of cardiomyopathy associated with doxorubicin administration. **2. Why the other options are incorrect:** * **Amifostine:** A cytoprotective agent (free radical scavenger) used primarily to reduce nephrotoxicity associated with **Cisplatin** and xerostomia in radiotherapy. * **Leucovorin (Folinic Acid):** Used as a "rescue" therapy to prevent bone marrow toxicity after high-dose **Methotrexate** or to potentiate the action of 5-Fluorouracil. * **Vitamin C:** While an antioxidant, it has no proven clinical role in preventing anthracycline-induced cardiotoxicity and is not used in standard oncological protocols for this purpose. **3. NEET-PG High-Yield Pearls:** * **Doxorubicin Toxicity:** Look for "Dilated Cardiomyopathy" or "Congestive Heart Failure" in clinical vignettes [1]. * **Monitoring:** Periodic **ECHO or MUGA scans** are mandatory to monitor the Left Ventricular Ejection Fraction (LVEF) [1]. * **Cumulative Dose:** Risk increases significantly when the cumulative dose of Doxorubicin exceeds **450–550 mg/m²** [1]. * **Mnemonic for CHOP:** **C**yclophosphamide, **H**ydroxydaunorubicin (Doxorubicin), **O**ncovin (Vincristine), **P**rednisolone.

Q: Which of the following is a common side effect of cisplatin?

Vomiting. **Explanation:** **Cisplatin** is a potent platinum-based alkylating agent used for various solid tumors. It is classified as a **highly emetogenic** drug. 1. **Why Vomiting is Correct:** Cisplatin is notorious for causing severe nausea and vomiting. It triggers the release of serotonin from enterochromaffin cells in the GI tract and directly stimulates the **Chemoreceptor Trigger Zone (CTZ)** in the medulla. It causes both acute (within 24 hours) and delayed emesis. Management typically requires a combination of 5-HT3 antagonists (e.g., Ondansetron), NK1 receptor antagonists (e.g., Aprepitant), and Dexamethasone. 2. **Why Other Options are Incorrect:** * **Diarrhea:** While some chemotherapeutic agents (like Irinotecan or 5-Fluorouracil) are known for causing severe diarrhea, it is not the hallmark side effect of Cisplatin. * **Pulmonary Fibrosis:** This is the classic dose-limiting toxicity of **Bleomycin** and **Busulfan**, not Cisplatin. * **Alopecia:** While many anticancer drugs cause hair loss, it is relatively less common or less severe with Cisplatin compared to Taxanes, Doxorubicin, or Cyclophosphamide. **High-Yield Clinical Pearls for NEET-PG:** * **Dose-limiting toxicity:** Nephrotoxicity (prevented by aggressive **Amifostine** and hydration). * **Ototoxicity:** High-frequency hearing loss and tinnitus (often irreversible). * **Peripheral Neuropathy:** "Glove and stocking" distribution. * **Mnemonic:** Remember the **"3 N's"** of Cisplatin: **N**ausea/Vomiting, **N**ephrotoxicity, and **N**eurotoxicity (including Ototoxicity).

Q: Which of the following is a known side effect associated with the chemotherapeutic agent Cisplatin?

Renal failure. **Cisplatin** is a platinum-based alkylating agent widely used for solid tumors. Its most significant dose-limiting toxicity is **Nephrotoxicity (Renal Failure)**. ### 1. Why Renal Failure is Correct Cisplatin accumulates in the proximal convoluted tubule (PCT) cells of the kidney, leading to oxidative stress and apoptosis. This manifests as a decrease in GFR and an increase in serum creatinine. To prevent this, clinicians use **aggressive hydration with normal saline** and the administration of **Amifostine** (a cytoprotective free-radical scavenger). ### 2. Analysis of Incorrect Options * **A. Hemorrhagic cystitis:** This is the classic side effect of **Cyclophosphamide** and **Ifosfamide** due to the metabolite **Acrolein**. It is prevented by **MESNA**. * **C. Tympanic membrane fibrosis:** While Cisplatin causes **Ototoxicity** (high-frequency hearing loss and tinnitus), it is due to damage to the **hair cells in the Organ of Corti**, not fibrosis of the tympanic membrane. * **D. Necrotizing enterocolitis:** This is primarily a neonatal gastrointestinal emergency, not a recognized specific side effect of Cisplatin therapy. ### 3. High-Yield Clinical Pearls for NEET-PG * **Mnemonic for Cisplatin Side Effects:** "3 N's" — **N**ephrotoxicity, **N**eurotoxicity (peripheral neuropathy), and **N**ausea/vomiting (it is highly emetogenic). * **Electrolyte Imbalance:** Cisplatin frequently causes **Hypomagnesemia** and hypokalemia due to renal tubular damage. * **Drug of Choice for Vomiting:** For Cisplatin-induced emesis, the regimen of choice is a **5-HT3 antagonist (Ondansetron) + Dexamethasone + NK1 antagonist (Aprepitant).** * **Carboplatin:** A related drug that is less nephrotoxic but more **myelosuppressive** (causes thrombocytopenia).

Q: Which drug is the best treatment for estrogen-positive breast cancer?

Tamoxifen. **Explanation:** **Tamoxifen (Option A)** is the gold standard and first-line treatment for hormone receptor-positive (ER/PR+) breast cancer in both pre- and post-menopausal women. It belongs to the class of **Selective Estrogen Receptor Modulators (SERMs)**. Its mechanism involves competitive antagonism of estrogen receptors in breast tissue, thereby inhibiting the growth of estrogen-dependent cancer cells. **Analysis of Incorrect Options:** * **Clomifene (Option B):** While also a SERM, it acts primarily on the hypothalamus to block the feedback inhibition of estrogen. This increases GnRH, FSH, and LH, making it a drug of choice for **ovulation induction** in infertility, not cancer. * **Glutethimide (Option C):** This is an older sedative-hypnotic drug (similar to barbiturates) with no role in oncology. * **5-Fluorouracil (Option D):** An antimetabolite (pyrimidine analog) used in various chemotherapy regimens (e.g., CMF). While used in breast cancer, it is not specific to estrogen-positive status and is generally a second-line or adjuvant cytotoxic choice compared to targeted hormonal therapy. **High-Yield Clinical Pearls for NEET-PG:** * **Dual Action:** Tamoxifen is an **antagonist in the breast** but an **agonist in the endometrium and bone**. * **Side Effects:** Due to its agonist effect on the uterus, it increases the risk of **endometrial carcinoma** and thromboembolism (DVT/PE). However, it helps prevent osteoporosis. * **Drug of Choice:** For post-menopausal ER+ breast cancer, **Aromatase Inhibitors** (e.g., Anastrozole, Letrozole) are now often preferred over Tamoxifen, but Tamoxifen remains the classic correct answer for general ER+ management in exams.

Q: Panitumumab is used for which of the following conditions?

Colorectal Carcinoma. **Explanation:** **Panitumumab** is a recombinant, fully humanized monoclonal antibody that targets the **Epidermal Growth Factor Receptor (EGFR)**. By binding to the extracellular domain of EGFR, it inhibits downstream signaling pathways (like RAS-RAF-MAPK) that promote cell proliferation and survival. * **Why Colorectal Carcinoma is correct:** Panitumumab is specifically indicated for the treatment of **metastatic Colorectal Carcinoma (mCRC)**. It is used in patients whose tumors express wild-type **KRAS** (non-mutated). If the KRAS gene is mutated, the signaling pathway remains "permanently on" regardless of EGFR inhibition, making the drug ineffective. **Analysis of Incorrect Options:** * **Multiple Sclerosis:** This is an autoimmune demyelinating disease. Drugs used here include Ocrelizumab (anti-CD20) or Natalizumab (anti-alpha-4 integrin), not EGFR inhibitors. * **Osmotic Diarrhea:** This is a physiological state caused by poorly absorbed solutes (e.g., lactulose or magnesium salts). It is not a clinical indication for monoclonal antibodies. * **Ascites:** This is a clinical sign of portal hypertension or malignancy. While treating the underlying cancer might reduce ascites, Panitumumab is not a direct treatment for the fluid accumulation itself. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** EGFR (ErbB1) Inhibitor. * **Genetic Testing:** Always check for **KRAS/NRAS mutations** before prescribing. It only works in **Wild-type** cases. * **Key Side Effect:** **Acneiform skin rash** (the severity of the rash often correlates with a better therapeutic response). * **Comparison:** **Cetuximab** is another EGFR inhibitor used for mCRC, but it is a chimeric antibody, whereas Panitumumab is fully humanized (lower risk of infusion reactions).

Q: Flutamide is used in which type of cancer?

Prostate. **Explanation:** **Flutamide** is a non-steroidal, competitive **androgen receptor antagonist**. Its primary mechanism involves blocking the binding of dihydrotestosterone (DHT) and testosterone to their receptors in target tissues. Since prostate cancer cells are typically androgen-dependent for growth and proliferation, blocking these receptors inhibits tumor progression. * **Why Prostate is Correct:** Prostate cancer is the classic indication for anti-androgens. Flutamide is frequently used in "Combined Androgen Blockade" (CAB) alongside GnRH agonists (like Leuprolide). This combination prevents the "testosterone flare" (a transient rise in testosterone) that occurs when GnRH agonists are first initiated. * **Why other options are incorrect:** * **Cervix:** Cervical cancer is primarily associated with HPV infection and is treated with surgery, radiation, or platinum-based chemotherapy (e.g., Cisplatin), not hormonal therapy. * **Kidneys:** Renal Cell Carcinoma (RCC) is managed with surgery, tyrosine kinase inhibitors (e.g., Sunitinib), or immunotherapy. * **Liver:** Hepatocellular carcinoma is treated with multi-kinase inhibitors like Sorafenib. **High-Yield Clinical Pearls for NEET-PG:** 1. **Side Effects:** The most characteristic side effect of Flutamide is **gynecomastia** (due to increased peripheral conversion of androgens to estrogen) and potential **hepatotoxicity** (requires monitoring of LFTs). 2. **Bicalutamide:** A newer congener of Flutamide, preferred nowadays due to its once-daily dosing and lower risk of hepatotoxicity. 3. **Cyproterone Acetate:** Another anti-androgen, but unlike Flutamide, it also has progestational activity and inhibits LH secretion.

Q: Which immunostimulant is used for the treatment of malignant melanoma?

Aldesleukin. **Explanation:** **Aldesleukin (Option C)** is a recombinant form of **Interleukin-2 (IL-2)**. It acts as an immunostimulant by promoting the proliferation and activation of T-cells and Natural Killer (NK) cells, enhancing the body’s immune response against tumor cells. It is specifically FDA-approved and clinically indicated for the treatment of **metastatic renal cell carcinoma** and **metastatic malignant melanoma**. **Analysis of Incorrect Options:** * **Levamisole (Option A):** Historically used as an adjuvant in colorectal cancer (with 5-FU) and for its anthelmintic properties. It is no longer a primary choice for melanoma. * **BCG (Option B):** While an immunostimulant, its primary oncological use is intravesical therapy for **superficial bladder cancer**. It is not the systemic treatment of choice for malignant melanoma. * **Methotrexate (Option D):** This is an antimetabolite (folic acid antagonist) and an **immunosuppressant/cytotoxic** drug, not an immunostimulant. **High-Yield Clinical Pearls for NEET-PG:** 1. **Capillary Leak Syndrome:** The most characteristic and life-threatening side effect of Aldesleukin (IL-2). It leads to hypotension, edema, and multiorgan failure. 2. **Other Melanoma Drugs:** Modern management also includes BRAF inhibitors (**Vemurafenib**) for BRAF V600E mutations and Immune Checkpoint Inhibitors like **Ipilimumab** (CTLA-4 inhibitor) and **Pembrolizumab** (PD-1 inhibitor). 3. **Interferon-alpha:** Another cytokine used in melanoma, primarily for adjuvant therapy in high-risk cases.

Q: Which of the following is an approved drug for prostate cancer?

Apalutamide. **Explanation:** **Apalutamide** is a potent, second-generation **androgen receptor (AR) antagonist**. It works by binding directly to the ligand-binding domain of the AR, preventing androgen binding, nuclear translocation, and DNA binding. It is FDA-approved for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). **Analysis of Options:** * **Bicalutamide (Option A):** While this is a first-generation anti-androgen used in prostate cancer, the question asks for the "approved drug" in a context where modern oncology exams prioritize newer, high-potency agents. In clinical practice, second-generation agents like Apalutamide or Enzalutamide are preferred due to their superior efficacy and lack of partial agonist activity. * **Ibalizumab (Option C):** This is a **CD4-directed post-attachment inhibitor** used in the management of multidrug-resistant HIV-1 infection. It is a monoclonal antibody, not an anticancer drug. * **Ivacaftor (Option D):** This is a **CFTR potentiator** used in the treatment of Cystic Fibrosis (specifically for patients with the G551D mutation). **NEET-PG High-Yield Pearls:** * **Second-generation AR Antagonists:** Apalutamide, Enzalutamide, and Darolutamide. Unlike Bicalutamide, these do not exhibit agonist activity when AR is overexpressed. * **Side Effects of Apalutamide:** Notable for causing skin rash, hypothyroidism, and an increased risk of seizures (due to GABA-A inhibition). * **Mechanism of Prostate Cancer Drugs:** * GnRH Agonists (Leuprolide) – Initial flare, then down-regulation. * GnRH Antagonists (Degarelix) – No flare. * CYP17 Inhibitor (Abiraterone) – Blocks androgen synthesis.

Q: Which of the following is an anti-VEGF drug?

Bevacizumab. **Explanation:** **Bevacizumab** is a recombinant humanized monoclonal antibody that acts as a potent **anti-VEGF (Vascular Endothelial Growth Factor)** agent. It binds directly to circulating VEGF-A, preventing it from interacting with its receptors (VEGFR-1 and VEGFR-2) on the surface of endothelial cells. This inhibits **angiogenesis** (the formation of new blood vessels), thereby "starving" the tumor of the blood supply required for growth and metastasis. It is clinically used in the treatment of metastatic colorectal cancer, renal cell carcinoma, and age-related macular degeneration (AMD). **Analysis of Incorrect Options:** * **Adalimumab:** A monoclonal antibody against **TNF-α** (Tumor Necrosis Factor-alpha). It is primarily used in chronic inflammatory conditions like Rheumatoid Arthritis, Psoriasis, and Crohn’s disease. * **Cetuximab:** A monoclonal antibody that targets the **EGFR** (Epidermal Growth Factor Receptor). It is used in the treatment of KRAS wild-type colorectal cancer and head and neck cancers. * **Daclizumab:** An antibody against the **IL-2 receptor (CD25)**. It was historically used to prevent renal transplant rejection and in multiple sclerosis (though largely withdrawn due to hepatic toxicity). **High-Yield Clinical Pearls for NEET-PG:** * **Adverse Effects of Bevacizumab:** The most characteristic side effects are **hypertension**, impaired wound healing, and gastrointestinal perforation. * **Suffix Trick:** Monoclonal antibodies ending in **"-umab"** are fully human, while **"-ximab"** are chimeric. * **Other Anti-VEGF agents:** **Ranibizumab** (fragment used for AMD) and **Aflibercept** (a "VEGF trap" fusion protein).

Question 1

Which is the most cardiotoxic anticancer drug class?

Accepted Answer

Anthracyclines

Answer

Alkylating agents

Answer

Platinum compounds

Answer

Bisphosphonates

Question 2

A patient with Non-Hodgkin's Lymphoma (NHL) is being treated with the CHOP chemotherapy regimen. Which of the listed agents is most likely to be protective against the cardiotoxicity associated with doxorubicin?

Accepted Answer

Dexrazoxane

Answer

Amifostine

Answer

Leucovorin

Answer

Vitamin C

Question 3

Which of the following is a common side effect of cisplatin?

Accepted Answer

Vomiting

Answer

Diarrhea

Answer

Pulmonary fibrosis

Answer

Alopecia

Question 4

Which of the following is a known side effect associated with the chemotherapeutic agent Cisplatin?

Accepted Answer

Renal failure

Answer

Hemorrhagic cystitis

Answer

Tympanic membrane fibrosis

Answer

Necrotizing enterocolitis

Question 5

Which drug is the best treatment for estrogen-positive breast cancer?

Accepted Answer

Tamoxifen

Answer

Clomifene

Answer

Glutethemide

Answer

5-FU

Question 6

Panitumumab is used for which of the following conditions?

Accepted Answer

Colorectal Carcinoma

Answer

Multiple Sclerosis

Answer

Osmotic diarrhea

Answer

Ascites

Question 7

Flutamide is used in which type of cancer?

Accepted Answer

Prostate

Answer

Cervix

Answer

Kidneys

Answer

Liver

Question 8

Which immunostimulant is used for the treatment of malignant melanoma?

Accepted Answer

Aldesleukin

Answer

Levamisole

Answer

BCG

Answer

Methotrexate

Question 9

Which of the following is an approved drug for prostate cancer?

Accepted Answer

Apalutamide

Answer

Bicalutamide

Answer

Ibalizumab

Answer

Ivacaftor

Question 10

Which of the following is an anti-VEGF drug?

Accepted Answer

Bevacizumab

Answer

Adalimumab

Answer

Cetuximab

Answer

Daclizumab

Anticancer Drugs — MCQs

Anticancer Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?